Description
Parkinson’s Disease Treatment Market Overview
The Parkinson’s Disease Treatment Market is expected to be valued at approximately USD 6.59 billion in 2024, grow to around USD 7.5 billion in 2025, and further increase to roughly USD 16.14 billion by 2034, exhibiting a Compound Annual Growth Rate (CAGR) of 8.9% from 2025 to 2034.
The market for Parkinson’s disease treatment is growing as the prevalence of the disease continues to rise. According to the Parkinson’s Foundation, approximately one million people in the United States are living with Parkinson’s disease, and about 60,000 new cases are diagnosed each year. As the population ages, the number of people living with Parkinson’s disease is expected to increase, driving demand for new and innovative treatment options.
One of the mainstays of treatment for Parkinson’s disease is medication. There are several classes of drugs that can help manage the symptoms of the disease, including levodopa, dopamine agonists, and MAO-B inhibitors. These medications work by either replacing or boosting the levels of dopamine in the brain, which is a neurotransmitter that is lacking in people with Parkinson’s disease.
In addition to medication, there are also non-pharmacological treatments that can help manage the symptoms of Parkinson’s disease. Physical therapy, occupational therapy, and speech therapy can all be beneficial in improving movement, balance, and speech in people with the disease. Exercise, such as yoga or tai chi, can also help improve flexibility and balance, while deep brain stimulation surgery may be recommended for those with severe tremors or motor fluctuations.
Parkinson’s Disease Treatment Market Dynamics
Drivers
Advances in medical research have led to the development of new treatment options for Parkinson’s disease.
Increased awareness and early diagnosis have improved outcomes for patients.
Growing emphasis on holistic approaches to managing Parkinson’s symptoms, including exercise and nutrition.
Restraints
Limited access to specialized care and resources in certain geographic areas.
High cost of medication and specialized therapies.
Stigma and lack of understanding about Parkinson’s disease can affect quality of life for patients.
Challenges
Finding the right balance of medication to manage symptoms without side effects.
Adapting to changes in mobility and daily activities.
Dealing with the emotional impact of a chronic disease diagnosis.
Opportunities
Participation in clinical trials to explore cutting-edge treatment options.
Accessing support groups and resources for education and emotional support.
Advocating for policy changes to improve access to care and research funding.
List of Key Players
- AbbVie
- Teva Pharmaceutical Industries
- Novartis
- GlaxoSmithKline (GSK)
- Merck & Co.
- Boehringer Ingelheim
- Lundbeck
- Amneal Pharmaceuticals
- Supernus Pharmaceuticals
- Acorda Therapeutics
- Medtronic (DBS devices)
- Mitsubishi Tanabe Pharma
- BlueRock Therapeutics (cell therapy)
- Bayer (via BlueRock)
- Olatec Therapeutics (dapansutrile)
- Cure Parkinson’s / Van Andel Institute partners
- Neurolixis
- Bristol-Myers Squibb
- Biogen
- UCB
Recent Developments:
Mitsubishi Tanabe Pharma America – May 22, 2025
FDA accepted the NDA resubmission for ND0612, a continuous subcutaneous infusion of levodopa/carbidopa for motor fluctuation control.
Medtronic – February 24, 2025
FDA approved Medtronic’s Adaptive DBS system, enabling real-time brain stimulation adjustments for personalized Parkinson’s therapy.
BlueRock Therapeutics – April 16, 2025
Published 18-month Phase I data for bemdaneprocel (cell therapy for Parkinson’s); Phase III trials to begin in H1 2025.
Parkinson’s Disease Treatment Market Segmentation
By Drug Class
- Levodopa/Carbidopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT Inhibitors
- Anticholinergics
- Others
By Treatment Type
- Oral Medications
- Injectables (e.g., apomorphine infusion)
- Transdermal Patches
- Infusion Therapies (e.g., continuous levodopa/carbidopa infusion)
- Medical Devices (Deep Brain Stimulation: both continuous & adaptive)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Patient Care Setting
- Hospitals & Neurology Clinics
- Outpatient Clinics
Regional Market Insights: A Breakdown by Region
North America
In North America, the treatment of Parkinson’s disease is primarily focused on medication, physical therapy, and deep brain stimulation surgery. Medications such as levodopa, dopamine agonists, and MAO-B inhibitors are commonly prescribed to help control motor symptoms. Physical therapy can also be beneficial in improving balance and mobility. Deep brain stimulation surgery is a more invasive treatment option that involves implanting electrodes into the brain to help regulate abnormal brain activity.
Europe
In Europe, the approach to treating Parkinson’s disease is similar to that in North America, with a strong emphasis on medication and physical therapy. However, there is also a growing interest in alternative therapies such as acupuncture, yoga, and mindfulness practices. These complementary treatments can help manage symptoms and improve overall well-being for patients with Parkinson’s disease.
Asia
In Asia, traditional Chinese medicine and herbal remedies are often used in conjunction with Western medical treatments for Parkinson’s disease. Acupuncture and tai chi have been shown to have beneficial effects on motor symptoms and quality of life for patients. Additionally, there is a focus on holistic care and personalized treatment plans that take into account cultural beliefs and practices.
Latin America
In Latin America, access to healthcare resources can vary widely depending on the country and region. While medication and physical therapy are commonly used treatments for Parkinson’s disease, there is also a need for increased awareness and education about the condition. Non-profit organizations and patient advocacy groups play a crucial role in advocating for better care and support for individuals with Parkinson’s disease in Latin America.
Target Audience
Pharmaceutical & Biotech Companies
Medical Device Manufacturers
Hospitals & Neurology Clinics
Specialty Pharmacies (Hospital, Retail, Online)
Contract Research/Manufacturing Organizations (CROs/CDMOs)
Regulatory Agencies
Health Insurance Providers & Payers
Investors & Venture Funds
Neurology & Clinical Research Institutions
Patient Advocacy & Support Organizations (e.g., Cure Parkinson’s)
